WALTHAM, Mass.--(BUSINESS WIRE)--Affinia Therapeutics (“Affinia”), an innovative gene therapy company with a pipeline of first-in-class and/or best-in-class adeno-associated virus (AAV) gene therapies ...
A new gene therapy approach aimed at protecting people with type 1 diabetes from developing diabetic kidney disease—a serious and common complication of the condition, has shown promising results in a ...
A recent study led by the UAB demonstrates the potential of gene therapy to restore motor capacity in an ultra-rare disease, megalencephalic leukoencephalopathy with subcortical cysts (MLC), even when ...
Immatics N.V., a clinical-stage biopharmaceutical company, announced that it will present data on its lead cell therapy candidate, IMA203 TCR T-cell therapy targeting PRAME, at the upcoming 2025 ASCO ...
Berlin, Germany – April 7, 2025 — With antimicrobial resistance rising as one of the world's most pressing health threats, the 8th World Congress on Targeting Phage Therapy 2025 will bring together ...
Labroots and the Cell & Gene Therapy planning committee are thrilled to announce the 2nd Annual Cell & Gene Therapy Virtual Event Series, live on October 15, 2025. This free, interactive event brings ...
It is a great pleasure to announce that Professor Robert T. Schooley, from the University of California, San Diego (USA), will be a keynote speaker at the 8th World Congress on Targeting Phage Therapy ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results